Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95

Arthritis and Rheumatism

Volumn 43, Issue 11, 2000, Pages 2550-2562

  Sgonc, Roswitha ^a   Gruschwitz, Matthias S ^b   Boeck, Guenther ^a   Sepp, Norbert ^a   Gruber, Johann ^a   Wick, Georg ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; ANTIGENS, CD95; APOPTOSIS; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; UMBILICAL VEINS;

EID: 0033758304     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200011)43:11<2550::AID-ANR24>3.0.CO;2-H     Document Type: Article

References (67)

1. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma
2. Systemic scleroderma: Clinical and pathophysiologic aspects
3. The pathogenesis of scleroderma (systemic sclerosis, SSc)
4. The aetiopathogenesis of systemic sclerosis
5. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma)
6. Polyclonal B lymphocyte activation in progressive systemic sclerosis
7. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity
8. Immunopathogenesis of systemic sclerosis
9. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-γ and tumor necrosis factor a in the early disease stage
10. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis
11. Sequential dermal microvascular and perivascular changes in the development of scleroderma
12. Immunologic aspects of scleroderma
13. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon
14. Characterization of the endothelial surface proteins recognized by anti-endothelial antibodies in primary and secondary autoimmune vasculitis
15. Anti-endothelial cell antibodies and autoimmune diseases
16. Measurement and characterization of circulating anti-endothelial cell IgG in connective tissue diseases
17. Anti-endothelial cell antibodies in patients with various forms of vasculitis
18. Antiendothelial cell antibodies: Useful markers of systemic sclerosis
19. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro: Induction of adhesion molecule expression and involvement of endothelium-derived cytokines
20. The effects of scleroderma serum on human microvascular endothelial cells: Induction of antibody-dependent cellular cytotoxicity
21. Antibody-dependent cellular cytotoxicity of vascular endothelium: Characterization and pathogenic associations in systemic sclerosis
22. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis
23. Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis
24. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis
25. Biology of natural killer cells
26. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis
27. Vascular disease in progressive systemic sclerosis (scleroderma)
28. Capillary alterations in scleroderma
29. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: Direct evidence for a generalized microangiopathy
30. Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells
31. Expression of extracellular matrix genes in adult human dermal microvascular endothelial cells and their regulation by heparin and endothelial cell mitogens
32. Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture
33. The 1982 revised criteria for the classification of systemic lupus erythematosus
34. Derivation of the SLEDAI: A disease activity index for lupus patients
35. Klinik der progressiven systemischen Sklerodermie (PSS)
36. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
37. A modified scleroderma skin scoring method
38. Antigenic features of human follicle stimulating hormone delineated by monoclonal antibodies and construction of an immunoradiometric assay
39. Polarized expression and basic fibroblast growth factor-induced down-regulation of the alpha 6 beta 4 integrin complex on human microvascular endothelial cells
40. Metalloproteinase-mediated release of human fas ligand
41. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and fas-based lytic pathways in cell-mediated cytotoxicity
42. Simultaneous determination of cell surface antigens and apoptosis
43. Scleroderma-like disorders
44. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus
45. Cytotoxicity to endothelial cells by sera from aged MRL/lpr/lpr mice is associated with autoimmunity to cell surface heparan sulfate
46. Cell death mechanisms and the immune system
47. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic lupus erythematosus
48. Human dermal microvascular endothelial cells: An improved method for tissue culture and a description of some singular properties in culture
49. Mechanism of sustained E-selectin expression in cultured human dermal microvascular endothelial cells
50. MHC class II expression on human heart microvascular endothelial cells: Exquisite sensitivity to interferon-gamma and natural killer cells
51. Human umbilical vein and dermal microvascular endothelial cells show heterogeneity in response to PKC activation
52. Differential expression of cell surface glycoproteins on various organ-derived microvascular endothelia and endothelial cell cultures
53. Anti-endothelial cell antibodies: Only for scientists or for clinicians too?
54. Mosaic of anti-endothelial antibodies. Review of the first international workshop on anti-endothelial antibodies: Clinical and pathological significance Milan, 9 November 1994
55. Anti-endothelial cell antibodies in systemic sclerosis
56. Endothelial injury in internal organs of UCD 200 chickens, an animal model for systemic sclerosis
57. Comparison between human IgM and IgG antibodies to dextran, regarding their activities in antibody-dependent cellular cytotoxicity (ADCC)
58. Radiation-induced apoptosis in microvascular endothelial cells
59. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: Balance between growth and death signals
60. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
61. Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12
62. Cytokine production and serum levels in systemic sclerosis
63. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma
64. Dual mechanisms of apoptosis induction by cytotoxic lymphocytes
65. Mechanism of serum-mediated endothelial injury in scleroderma: Identification of a granular enzyme in scleroderma skin and sera
66. Acidification is essential for maintaining the structure and function of lytic granules of CTL: Effect of concanamycin A, an inhibitor of vacuolar type H(+)-ATPase, on CTL-mediated cytotoxicity
67. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis